KIFFIK is developing a platform designed to enable direct access to interstitial fluid (ISF), where signals first appear.
Interstitial fluid surrounds living cells and reflects local biology. Biomarkers originate in tissue and appear in ISF before dilution and systemic clearance in the bloodstream.
KIFFIK's platform is designed to enable access to this historically underutilized biological fluid, supporting research, clinical investigation, and future monitoring applications.
KIFFIK's platform is enabled by proprietary K-EXP™
technology, designed to support direct access to ISF and the generation of biological information across research and development applications.
Biology becomes valuable when it can be accessed. KIFFIK's platform connects direct access to ISF with multiple development pathways across human and animal health.
The KIFFIK platform, enabled by proprietary K-EXP™ technology, is being developed to support multiple application pathways through direct access to biology, enabled by ISF.
Advancing biomarker discovery and drug development through direct access to biology. Enabling deeper understanding of therapeutic response, PK/PD relationships, and disease biology.
Colorectal cancer is the lead development program, with future expansion opportunities across prostate, pancreatic, breast, and other oncology applications.
Advancing tissue-level biomarker access for neurological disease, with Alzheimer's disease and traumatic brain injury (TBI) serving as leading development programs.
Advancing biological monitoring beyond single-analyte sensing through multiplex biomarker measurement, with lead programs in metabolic monitoring and sepsis detection.
Expanding access to biology in veterinary medicine, with lead programs in equine fertility and bovine dairy health monitoring.
Direct access to biology creates opportunities across biomarker discovery, drug development, disease monitoring, and animal health. KIFFIK is advancing multiple development programs enabled by access to interstitial fluid.
